Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Coats Group raises £246m to help fund OrthoLite acquisition

(Sharecast News) - Coats Group said on Thursday that it has successfully raised gross proceeds of approximately £246m through a capital raise aimed at funding its acquisition of OrthoLite Holdings. The FTSE 250 company said the transaction received strong backing from existing shareholders and institutional investors.

A total of 319.6 million new ordinary shares were issued, representing around 20% of Coats' pre-raise issued share capital.

That, the firm said, included 314.8 million shares placed by BNP Paribas and Peel Hunt with institutional investors at 77p per share, a 6.2% discount to the prior day's closing price.

Retail investors subscribed for an additional 3.85 million shares via the RetailBook platform, while directors and senior management purchased a combined 902,595 shares.

The funds would be used to partly finance Coats' previously announced acquisition of OrthoLite, a move described by the company as a strategic expansion into high-growth, high-margin markets.

Coats Group released further details of the acquisition in a separate statement on 16 July.

Admission of the new shares to trading on the London Stock Exchange was expected to take place on 21 July at 0800 BST.

On completion, Coats' total ordinary shares in issue would rise to about 1.92 billion.

At 0918 BST, shares in Coats Group were down 11.26% at 72.85p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.